PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA INCLUDING COMPREHENSIVE EXPLORATORY AML PROFILING AND EVALUATION OF EX VIVO DRUG SENSITIVITY AND RESISTANCE SCREENING
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms LD-VenEx
Most Recent Events
- 02 Feb 2022 New trial record